ONCY
Oncolytics Biotech Inc. (NASDAQ)
Healthcare — Biotechnology
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $107.50M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.82 |
| EPS (TTM) | $-0.32 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Buy 1.8 |
| Analyst Target | $4.93 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 61.9 |
| Beta | 1.08 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.51 |
| 52-Week Low | $0.77 |
| 50-Day Avg | $0.91 |
| 200-Day Avg | $1.02 |
| Avg Volume | $1.33M |
| Volume | 649.4K |
Performance Analysis
BULLISHONCY shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:24 UTC
Back to Screener Export Report